miRNA-520c-3p accelerates progression of nasopharyngeal carcinoma via targeting RAB22A

XIAOHAN SUN, WENRUI XU, CHUANSHAN ZANG and NA LI

Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China

Received September 16, 2019; Accepted November 13, 2019

DOI: 10.3892/ol.2019.11144

Abstract. Biological function of microRNA-20c-3p (miRNA-520c-3p) in the progression of nasopharyngeal carcinoma (NPC) and the potential mechanism were investigated. Relative level of miRNA-520c-3p in NPC tissues and adjacent normal tissues was determined by quantitative real-time polymerase chain reaction (qRT-PCR). Particularly, miRNA-520c-3p level in NPC with different tumor stages and tumor sizes was examined. Subsequently, miRNA-520c-3p level in nasopharyngeal epithelial cells and NPC cells was detected. The potential influence of miRNA-520c-3p on the proliferative ability and cell cycle progression of NPC cells were evaluated through cell counting kit-8 (CCK-8) and flow cytometry. The target gene of miRNA-520c-3p was verified by dual-luciferase reporter gene assay. Regulatory role of miRNA-520c-3p/RAB22A in the malignant progression of NPC was identified. miRNA-520c-3p was downregulated in NPC tissues and cell lines. Its level was lower in NPC with worse tumor grade and larger tumor size. Overexpression of miRNA-520c-3p suppressed the proliferative ability and arrested cell cycle in G0/G1 phase. RAB22A was confirmed to be the downstream target of miRNA-520c-3p. In NPC tissues and cell lines, RAB22A remained in higher abundance relative to controls. Overexpression of RAB22A reversed the inhibitory effects of overexpressed miRNA-520c-3p on proliferative ability and cell cycle progression of NPC cells. miRNA-520c-3p is downregulated in NPC, which accelerates the malignant progression of NPC by targeting RAB22A.

Introduction

Nasopharyngeal carcinoma (NPC) is a malignant tumor growing on the top and lateral side of the nasopharyngeal cavity. It is one of the common high-grade malignant tumors in China, and the incidence ranks the first of the malignant tumors of the ear, nose and throat (1). Typical symptoms of NPC include nasal congestion or bleeding, hearing loss, diplopia and headache (2). Non-keratinized squamous cell carcinoma is the major subtype of NPC, which has high malignancy and high rate of distant metastasis due to local infiltration (3). Environmental factors, genetic susceptibility and EBV (Epstein-Barr virus) infection are the major causes of NPC (4). Unfortunately, ~30-40% of NPC patients are diagnosed at advanced stage accompanied by distant metastasis or local recurrence since diagnostic methods at early stage are insufficient (5). It is urgent to uncover the pathogenesis of NPC and to search for hallmarks that help in diagnosis and treatment at early stage.

MicroRNAs (miRNAs) are a class of non-coding, single-stranded RNAs encoded by endogenous genes ~22 nucleotides long. They participate in post-transcriptional regulation. A single miRNA could have several target genes, and several miRNAs could regulate one common gene. Approximately one-third of human genes could be regulated by miRNAs. It is reported that miRNA exerts a crucial function in the occurrence and progression of NPC (6). For example, miR-184 inhibits NPC cells to migrate and invade by modulating Notch2 (7). miR-342 directly inhibits the growth and metastasis of NPC cells through targeting ZEB1 (8). miR-495 downregulates GRP78 expression by regulating epithelial-mesenchymal transition (EMT), thus enhancing the radiotherapy-sensitivity of NPC (9).

Previous studies have found that HOXA-AS2 promotes proliferation and induces EMT in hepatocellular carcinoma via the microRNA-520c-3p (miRNA-520c-3p)/GPC3 axis (10). LncRNA HOXA-AS2 promotes the progression of papillary thyroid carcinoma by regulating the miRNA-520c-3p/S100A4 pathway (11). Serving as a ceRNA, it accelerates osteosarcoma cells to migrate and invade by sponging miRNA-520c-3p (12). miRNA-520c-3p negatively regulates EMT by targeting IL-8, thus inhibiting the metastasis of breast cancer (13). miRNA-520c-3p is reported to be involved in tumor progression. However, its role in the progression of NPC has not been fully elucidated.

RAB22A is a member of the Ras superfamily, with a carcinogenic role (14,15). Previous studies have demonstrated that RAB22A is upregulated in several types of tumors (16-19).

Correspondence to: Dr Na Li, Department of Otolaryngology Head and Neck Surgery, The Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, Shandong 266003, P.R. China. E-mail: shnix671@163.com

Key words: nasopharyngeal carcinoma, miRNA-520c-3p, RAB22A, proliferation, cell cycle
A relevant study pointed out that upregulated RAB22A in breast cancer is closely related to lymphatic metastasis and malignant progression (20). In this study, we first determined the expression pattern of miRNA-520c-3p in NPC. Correlation between miRNA-520c-3p level and pathological indexes of NPC patients was analyzed. Subsequently, RAB22A was predicted to be the target gene of miRNA-520c-3p. The biological function of miRNA-520c-3p/RAB22A axis in the malignant progression of NPC was further explored.

Patients and methods

Sample collection. NPC tissues and normal adjacent tissues were surgically resected from NPC patients in The Affiliated Hospital of Qingdao University (Qingdao, China) from December 2016 to October 2018. They did not receive preoperative anti-tumor therapy and were pathologically diagnosed. Samples were immediately preserved in liquid nitrogen. All subjects volunteered to participate in the study and signed an informed consent. This study was approved by the Ethics Committee of The Affiliated Hospital of Qingdao University.

RNA extraction and quantitative real-time polymerase chain reaction (qRT-PCR). RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.), chloroform and isopropanol. The extracted RNA was quantified and reversely transcribed into complementary deoxyribonucleic acid (cDNA), followed by PCR using SYBR Green method. PCR was conducted at 94°C for 5 min, followed by 40 cycles at 94°C for 30 sec, 55°C for 30 sec and 72°C for 90 sec.

Cell culture and transfection. Nasopharyngeal epithelial cell line (NP69) and NPC cell lines (CNE1, 6-10B, SUNE2, HNE-1 and CNE2) were provided by American Type Culture Collection (ATCC). Cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640) (HyClone; GE Healthcare Life Sciences) containing 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.) and maintained at 37°C, in 5% CO2 incubator.

For transfection, cells were pre-seeded in a 6-well plate and grown to 60-80% confluence. Transfection reagent and Lipofactamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) were, respectively, diluted in serum-free medium. They were mixed together and left at room temperature for 20 min. Serum-free medium (1.5 ml) and 0.5 ml of transfection mixture were applied to each well. At 4-6 h, complete medium was replaced.

Cell counting kit-8 (CCK-8). Cells were seeded to wells of the 96-well plate with 2×104 cells/well. Absorbance (A) at 450 nm was recorded at the appointed time points using the CCK-8 kit (Dojindo Laboratories) for depicting the viability curve.

Western blot analysis. Total protein was extracted from cells or tissues using radioimmunoprecipitation assay (RIPA) (Beyotime Institute of Biotechnology) and loaded for electrophoresis. After transferring on a polyvinylidene fluoride (PVDF) membrane (EMD Millipore) at 300 mA for 100 min, it was blocked in 5% skim milk for 2 h, incubated with primary antibodies at 4°C overnight and secondary antibodies for 2 h. Bands were exposed by electrochemiluminescence (ECL) and analyzed by Image Software (NIH).

Flow cytometry. Cell density was adjusted to 5×104 cells/ml and fixed in pre-cold 75% ethanol overnight. Before cell cycle determination, cells were washed with phosphate-buffered saline (PBS) twice, incubated with 100 µl of RNaseA at 37°C water bath in the dark for 30 min, and then incubated with 400 µl of PI at 4°C in the dark for 30 min. Flow cytometry was used for determining the absorbance at 488 nm.

Coloncy formation assay. Cells were seeded in the culture dish with 50, 100 and 200 cells, respectively. After cell culture for 2-3 weeks, cells were subjected to 15 min fixation in 4% paraformaldehyde and 30-min Giemsa staining. After removing the staining solution, colonies were air dried and observed under a microscope. Percentage of colonies = colony number / cell number×100%.

Construction of LV-RAB22A. A plasmid containing the full-length cDNA of RAB22A and the H1 promoter fragment were amplified by PCR, and inserted into the lentivirus, which was LV-RAB22A.

Dual-luciferase reporter gene assay. Wild-type and mutant-type luciferase vectors of RAB22A were constructed, namely RAB22A WT and RAB22A MUT, respectively. Cells were co-transfected with RAB22A WT/MUT and miRNA-520c-3p mimics/NC for 24 h. Cells were then fully lysed, centrifuged at 10,000 x g at 4°C for 5 min, and 100 µl of supernatant was harvested for determining the luciferase activity (Promega).

Statistical analysis. Statistical Product and Service Solutions (SPSS) 19.0 (SPSS Inc.) was used for all statistical analysis. Data are presented as mean ± SD (standard deviation). The t-test was used for analyzing intergroup differences. P<0.05 was considered to indicate a statistically significant difference.

Results

miRNA-520c-3p is downregulated in NPC. Compared with adjacent non-tumor tissues, miRNA-520c-3p was downregulated in NPC tissues as qRT-PCR data revealed (Fig. 1A). Identically, it was downregulated in NPC cell lines relative to NP69 cell line (Fig. 1B). Based on different tumor stage, it is found that miRNA-520c-3p level remained higher in NPC with stage I+II relative to those with stage III+IV (Fig. 1C). Moreover, miRNA-520c-3p remained in higher abundance in NPC tissues with ≤5 cm in tumor size compared with those ≥5 cm (Fig. 1D). These data suggested the potential involvement of miRNA-520c-3p in the progression of NPC.

Knockdown of miRNA-520c-3p accelerated proliferative ability and cell cycle progression. To clarify the biological function of miRNA-520c-3p in NPC, we first constructed miRNA-520c-3p mimic and inhibitor. Their transfection efficacy was verified in SUNE2 and CNE2 cells (Fig. 2A). CCK-8 assay showed the inhibited viability in NPC cells overexpressing miRNA-520c-3p, while knockdown of miRNA-520c-3p enhanced the viability (Fig. 2B). After
Figure 1. miRNA-520c-3p is downregulated in NPC. (A) Relative level of miRNA-520c-3p in NPC tissues and adjacent non-tumor tissues. (B) Relative level of miRNA-520c-3p in nasopharyngeal epithelial cell line (NP69) and NPC cell lines (CNE1, 10B, SUNE2, HNE-1 and CNE2). (C) Relative level of miRNA-520c-3p in NPC with stage III-IV and stage I-II. (D) Relative level of miRNA-520c-3p in NPC tissues <5 cm and ≥5 cm. *P<0.05. miRNA-520c-3p, microRNA-520c-3p; NPC, nasopharyngeal carcinoma.

Figure 2. Knockdown of miRNA-520c-3p accelerates proliferative ability and cell cycle progression. (A) Transfection efficacy of miRNA-520c-3p mimic and inhibitor in SUNE2 and CNE2 cells. (B) CCK-8 assay showed the viability in SUNE2 and CNE2 cells transfected with miRNA-520c-3p mimic or inhibitor. (C) Flow cytometry showed the percentage of cell cycle in SUNE2 and CNE2 cells transfected with miRNA-520c-3p mimic or inhibitor. (D) Colony formation assay showed the number of colonies in SUNE2 and CNE2 cells transfected with miRNA-520c-3p mimic or inhibitor. *P<0.05. miRNA-520c-3p, microRNA-520c-3p; CCK-8, cell counting kit-8.
Figure 3. miRNA-520c-3p exerts the carcinogenic role by targeting RAB22A. (A) Binding sequences between miRNA-520c-3p and RAB22A. (B) Relative level of RAB22A in NPC tissues and adjacent non-tumor tissues. (C) Relative level of RAB22A in nasopharyngeal epithelial cell line (NP69) and NPC cell lines (CNE1, 6-10B, SUNE2, HNE-1 and CNE2). (D) Protein level of RAB22A in SUNE2 and CNE2 cells transfected with miRNA-520c-3p mimic or inhibitor. (E) Luciferase activity in SUNE2 and CNE2 cells co-transfected with RAB22A WT/MUT and miRNA-520c-3p mimics/NC. *P<0.05. miRNA-520c-3p, microRNA-520c-3p; NPC, nasopharyngeal carcinoma.

Figure 4. Overexpression of RAB22A reverses the carcinogenic role of overexpressed miRNA-520c-3p in NPC. (A) Transfection efficacy of LV-RAB22A in SUNE2 and CNE2 cells. (B) CCK-8 assay showed the viability in SUNE2 and CNE2 cells transfected with NC, miRNA-520c-3p mimic or miRNA-520c-3p mimic+LV-RAB22A. (C) Flow cytometry showed the percentage of cell cycle in SUNE2 and CNE2 cells transfected with NC, miRNA-520c-3p mimic or miRNA-520c-3p mimic+ LV-RAB22A. *P<0.05. miRNA-520c-3p, microRNA-520c-3p; NPC, nasopharyngeal carcinoma; CCK-8, cell counting kit-8.
transfection of miRNA-520c-3p mimic, SUNE2 and CNE2 cells were mainly arrested in G0/G1 phase (Fig. 2C). Knockdown of miRNA-520c-3p, conversely, accelerated the cell cycle progression. Similarly, the number of colonies markedly decreased in NPC cells overexpressing miRNA-520c-3p (Fig. 2D).

**miRNA-520c-3p exerts the carcinogenic role by targeting RAB22A.** Through online prediction, binding sequences between miRNA-520c-3p and RAB22A were revealed (Fig. 3A). RAB22A was highly expressed in NPC tissues and cell lines (Fig. 3B and C). Subsequently, western blot analyses indicated that transfection of miRNA-520c-3p mimic downregulated RAB22A, whereas transfection of miRNA-520c-3p inhibitor upregulated its level (Fig. 3D). Dual-luciferase reporter gene assay was further conducted to elucidate the binding relationship between miRNA-520c-3p and RAB22A. Relative luciferase markedly decreased in NPC cells co-transfected with miRNA-520c-3p mimic and RAB22A WT, confirming the binding of RAB22A to miRNA-520c-3p (Fig. 3E).

**Overexpression of RAB22A reverses the carcinogenic role of overexpressed miRNA-520c-3p in NPC.** A series of rescue experiments were performed to elucidate the role of miRNA-520c-3p/RAB22A in the malignant progression of NPC. LV-RAB22A was first constructed, and transfection of LV-RAB22A in SUNE2 and CNE2 cells markedly upregulated RAB22A level (Fig. 4A). Transfection of LV-RAB22A partially reversed the inhibited viability in NPC cells overexpressing miRNA-520c-3p (Fig. 4B). Identically, the arrested NPC cells in G0/G1 phase due to miRNA-520c-3p overexpression were reduced by co-transfection of LV-RAB22A (Fig. 4C). It is believed that overexpression of RAB22A reversed the carcinogenic role of miRNA-520c-3p in NPC.

**Discussion**

NPC originates from the nasopharyngeal mucosa epithelium, which is the most prevalent cancer in otolaryngology (21). Clinical symptoms of NPC are not obvious, mainly manifesting as nasal congestion and bleeding (22). Lymphatic metastasis of NPC develops at the early stage of NPC. Currently, radiotherapy is the preferred method for NPC treatment since the tumor is moderately sensitive to it (23). The prognosis of NPC is relatively poor because of high rates of recurrence and metastasis at early stage (24). Searching for specific hallmarks and therapeutic targets for NPC contributes to improve the prognosis of these patients.

miRNAs are small, non-coding RNAs. In plants, miRNA completely binds to the target gene to cleave the target mRNA (25). In animals, miRNA inhibits the translation of target gene by incompletely complementary pairing, which further mediates target gene expression without influencing the mRNA stability (26). Some miRNAs locate in tumor-related region on the chromosome. Serving as oncogenes or tumor-suppressor genes, they exert different roles in the whole process of tumor progression (27,28).

In this study, miRNA-520c-3p was downregulated in NPC tissues and cell lines, which is consistent with others that miRNA-520c-3p is downregulated in some malignant tumors. It was found that overexpression of miRNA-520c-3p suppressed proliferative ability and arrested cell cycle in G0/G1 phase. These results demonstrated that miRNA-520c-3p could be a tumor suppressor in the progression of NPC.

Subsequently, RAB22A was confirmed to be the direct target of miRNA-520c-3p. As a novel carcinogenic gene, RAB22A facilitates malignant phenotypes of tumor cells. A growing number of evidence has shown the vital function of RAB22A in tumorigenesis and tumor progression. RAB22A enhances CD147 cycle, which is necessary for invasion and migration of lung cancer cells (16). Overexpression of RAB22A accelerates the tumor growth of melanoma (29). The proliferative and invasive capacities of kidney cancer cells are suppressed by miR-204 mediated RAB22A (30). It was demonstrated that miRNA-520c-3p blocked proliferative progression of NPC cells via targeting RAB22A.

In conclusion, miRNA-520c-3p is downregulated in NPC, which accelerates the malignant progression of NPC by targeting RAB22A.

**Acknowledgements**

Not applicable.

**Funding**

Not applicable.

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article.

**Authors’ contributions**

XS and NL designed the study and performed the experiments, XS and WX collected the data, NL and CZ analyzed the data, XS and NL prepared the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

This study was approved by the ethics committee of The Affiliated Hospital of Qingdao University (Qingdao, China). Signed informed consents were obtained from the patients and/or guardians.

**Patient consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**References**

1. Ma YX, Zhang H, Li XH and Liu YH: miR-30e-5p inhibits proliferation and metastasis of nasopharyngeal carcinoma cells by targeting USP22. Eur Rev Med Pharmacol Sci 22: 6342-6349, 2018.
2. Lao TD, Nguyen TV, Nguyen DH, Nguyen MT, Nguyen CH and Le THA: miR-141 is up-regulated in biopsies from Vietnamese patients with nasopharyngeal carcinoma. Braz Oral Res 32: e126, 2018.

3. Chua MLK, Wee JTS, Hui EP and Chan ATC: Nasopharyngeal carcinoma. Lancet 387: 1012-1024, 2016.

4. Kamran SC, Riaz N and Lee N: Nasopharyngeal carcinoma. Surg Oncol Clin N Am 24: 547-561, 2015.

5. Lee AW, Ma BB, Ng WT and Chan AF: Management of nasopharyngeal carcinoma: Current practice and future perspective. J Clin Oncol 33: 3356-3364, 2015.

6. Lin CH, Chiang MC and Chen YJ: MicroRNA-328 inhibits migration and epithelial-mesenchymal transition by targeting CD44 in nasopharyngeal carcinoma cells. Oncotargets Ther 11: 2375-2385, 2018.

7. Zhu HM, Jiang XS, Li HZ, Qian LX, Du MY, Lu ZW, Wu J, Tian XK, Fei Q, He X, et al: miR-184 inhibits tumor invasion, migration and metastasis in nasopharyngeal carcinoma by targeting Notch2. Cell Physiol Biochem 49: 1564-1576, 2018.

8. Zhu X, Li W, Zhang R and Liu Y: MicroRNA-342 inhibits cell proliferation and invasion in nasopharyngeal carcinoma by directly targeting ZEB1. Oncol Lett 16: 1298-1304, 2018.

9. Feng X, Lv W, Wang S and He Q: miR-495 enhances the efficacy of radiotherapy by targeting GRP78 to regulate EMT in nasopharyngeal carcinoma cells. Oncol Rep 40: 1223-1232, 2018.

10. Zhang Y, Xu J, Zhang S, An J, Zhang J, Huang J and Jin Y: HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition via the miR-520c-3p/GPC3 axis in hepatocellular carcinoma. Cell Physiol Biochem 50: 2124-2138, 2018.

11. Xia F, Chen Y, Jiang B, Du X, Peng Y, Wang W, Huang W, Feng T and Li X: Long noncoding RNA HOXA-AS2 promotes papillary thyroid cancer progression by regulating miR-520c-3p/S100A4 pathway. Cell Physiol Biochem 50: 1659-1672, 2018.

12. Wang Y, Zhang R, Cheng G, Xu R and Han X: Long non-coding RNA HOXA-AS2 promotes migration and invasion by acting as a ceRNA of miR-520c-3p in osteosarcoma cells. Cell Cycle 17: 1637-1648, 2018.

13. Tang CP, Zhou HJ, Qin J, Luo Y and Zhang T: MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer cells. Oncol Rep 35: 3144-3152, 2017.

14. Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10: 513-525, 2009.

15. Zhang Y, Zhao FJ, Chen LL, Wang L, Nopheu KP, Wu YX and Zhang S: miR-373 targeting of the RAB22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget 5: 12291-12303, 2014.

16. Zhou Y, Wu B, Li JH, Nan G, Jiang J and Chen ZN: RAB22a enhances CD147 recycling and is required for lung cancer cell migration and invasion. Exp Cell Res 357: 9-16, 2017.

17. He H, Dai F, Yu L, Shu X, Zhou Y, Jing J, Chen X and Zhao S: Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr 10: 231-242, 2002.

18. Yin Y, Zhang B, Wang W, Fei B, Quan C, Zhang J, Song M, Bian Z, Wang Q, Ni S, et al: miR-204-5p inhibits proliferation and invasion and enhances chemotherapeutic sensitivity of colorectal cancer cells by downregulating RAB22A. Clin Cancer Res 20: 6187-6199, 2014.

19. Xia Z, Liu F, Zhang J and Liu L: Decreased expression of miR-204-5p contributes to glioma progression and promotes glioma cell growth, migration and invasion. PLoS One 10: e0132399, 2015.

20. Sun L, He M, Xu N, Xu DH, Ben-David Y, Yang ZY and Li YJ: Regulation of RAB22A by miR-193b inhibits breast cancer growth and metastasis mediated by exosomes. Int J Oncol 53: 2705-2714, 2018.

21. Lu J, Liu QH, Wang F, Tan JJ, Deng YQ, Peng XH, Liu X, Zhang B, Xu X and Li XP: Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/akt pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res 37: 147, 2018.

22. Zhen Y, Liu Z, Yang H, Yu X, Wu Q, Hua S, Long X, Jiang Q, Song Y, Cheng C, et al: Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 4: e872, 2013.

23. Yi M, Cai J, Li J, Chen S, Zeng Z, Peng Q, Ban Y, Zhou Y, Li X, Xiong W, et al: Rediscovery of NF-kB signaling in nasopharyngeal carcinoma: How genomic detects of NF-kB pathway interplay with HBV in driving oncogenesis? J Cell Physiol 235: 5537-5549, 2018.

24. Ma J, Xuan SH, Li Y, Zhang ZP and Li XH: Role of the TGF/β/PDCD4/AP-1 signaling pathway in nasopharyngeal carcinoma and its relationship to prognosis. Cell Physiol Biochem 45: 1390-1401, 2018.

25. Turner Y: miRNA and cancer; computational and experimental approaches. Curr Pharm Biotechnol 15: 429, 2014.

26. Perrin-Neagoe I, Monroy PC, Pasculli B and Calin GA: MicroRNome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin 64: 311-326, 2014.

27. Fendler A, Stephan C, Yousef GM and Jung K: MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem 57: 954-968, 2011.

28. Eullalia A, Hutzinger E and Izaurralde E: Getting to the root of post-translational modifications. Nat Rev Mol Cell Biol 18: 501-513, 2017.

29. Li F, Chen X and Su J: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol 10: 513-525, 2009.

30. Zhong F, Chen Y, Zhu S, Li F, Zhao S, Wu L, Chen X and Su J: Rab22a overexpression promotes the tumor growth of renal cell carcinoma by inhibiting Rab22a expression. Oncol Rep 35: 3000-3008, 2016.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.